|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Receivable from public grants | ||||||||||||||||||||
| Other receivables | ||||||||||||||||||||
| Assets held for sale, property and equipment | ||||||||||||||||||||
| German research and development tax credit receivable | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets, non-current | ||||||||||||||||||||
| Other non-current assets | ||||||||||||||||||||
| Operating lease right-of-use assets, net | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Deferred revenues, current portion | ||||||||||||||||||||
| Derivative liabilities - contingent value right liability | ||||||||||||||||||||
| Current portion of operating lease liability | ||||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Deferred revenue, net of current portion | ||||||||||||||||||||
| Long-term portion of operating lease liability | ||||||||||||||||||||
| Royalty agreement liability | ||||||||||||||||||||
| Derivative liabilities - royalty agreement | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Convertible preferred stock, $0.00001 par value; 0 and 20,655,895 shares authorized; 0 and 15,360,787 shares issued and outstanding at December 31, 2024 and 2023; aggregate liquidation value of $0 and $65,377 at December 31, 2024 and 2023 | ||||||||||||||||||||
| Stockholders' deficit: | ||||||||||||||||||||
| Preferred stock, $0.001; 10,000,000 shares authorized; 15,617 shares issued and outstanding at September 30, 2025 and December 31, 2024 | ||||||||||||||||||||
| Common stock, $0.001 par value; 200,000,000 shares authorized; 14,395,705 and 12,380,933 shares issued and outstanding at June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive (loss) income | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||||||
Loading...
